Search

Additional file 1: Table S1. Clinical baseline characteristics of 101 patients with HCC according to CEBPA-DT expression level. Table S2. Prognostic factors for overall survival and recurrence-free survival by the univariate Cox proportional hazards regression model. Table S3. Independent prognostic factors for overall survival and recurrence-free survival by the multivariate Cox proportional hazards regression model. Table S4. The antibodies used in this study. Table S5. Sequence of primers used for PCR in this study. Table S6. Sequence of siRNA and shRNA against specific target in this study.

Additional file 5: Table S4 Postoperative complications after matching.

Additional file 8: Table S6 Outcomes between OR extubation group and ICU extubation group (within 24h) after matching.

Additional file 1: Table S1. STROBE Statement. Checklist of our cohort study, which demonstrates STROBE Statement Checklist of our cohort study.

Additional file 7: Figure S2 Association between extubation in the OR and composite mechanical ventilation-related adverse outcomes.

Additional file 6: Table S5 Unplanned-Reintubation indications amongst OR extubation and ICU extubation groups after matching.

Additional file 4: Figure S1 Histograms of the estimated propensity scores.

Additional file 3: Table S3 Predefined Postoperative Complications According European Perioperative Clinical Outcome definitions.

Additional file 2: Table S2 Predefined Acute Kidney Injury (AKI) According Kidney Disease Improving Global Outcomes Guidelines (KIDGO).

Additional File 3: Table S1. Classification of Postoperative Complications

Background/aims The aim of this study was to evaluate the clinical efficacy of postoperative adjuvant transcatheter arterial chemoembolization (TACE) on hepatocellular carcinoma (HCC) with microscopic venous invasion. Methodology Data from 76 patients with HCC who underwent hepatectomy with or without postoperative adjuvant TACE between July 2005 and August 2010 were retrospectively reviewed. Kaplan-Meier method was used to compare survival between the groups and prognostic factors were evaluated by Cox proportional hazard model. Results The 1-, 3- and 5-year disease- free survival rates were 76.3%, 44.5% and 31.8%, respectively, for the adjuvant TACE group (35 patients) and 60.1%, 39.3% and 21.5%, respectively, for the control group (41 patients). The 1-, 3- and 5-year overall survival rates were 88.6%, 67.2% and 42.3%, respectively, for the TACE group and 77.5%, 58.0% and 40.5%, respectively, for the control group. Although improving trends of both disease-free survival and overall survival were observed in adjuvant TACE group, there was no significant difference between the two groups (p>0.05). Cox regression analysis revealed that tumor size and differentiation were significant independent prognostic factors. Conclusions Postoperative adjuvant TACE may improve 1, 3 and 5 year disease-free and overall survival rates of HCC patients with microscopic venous invasion but no statistical significance was found. It can be used as a preventative treatment but not a routine procedure for such patients.

Hereditary tyrosinemia type 1 (HT1) is a severe human autosomal recessive disorder caused by the deficiency of fumarylacetoacetate hydroxylase (FAH), an enzyme catalyzing the last step in the tyrosine degradation pathway. Lack of FAH causes accumulation of toxic metabolites (fumarylacetoacetate and succinylacetone) in blood and tissues, ultimately resulting in severe liver and kidney damage with onset that ranges from infancy to adolescence. This tissue damage is lethal but can be controlled by administration of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC), which inhibits tyrosine catabolism upstream of the generation of fumarylacetoacetate and succinylacetone. Notably, in animals lacking FAH, transient withdrawal of NTBC can be used to induce liver damage and a concomitant regenerative response that stimulates the growth of healthy hepatocytes. Among other things, this model has raised tremendous interest for the in vivo expansion of human primary hepatocytes inside these animals and for exploring experimental gene therapy and cell-based therapies. Here, we report the generation of FAH knock-out rabbits via pronuclear stage embryo microinjection of transcription activator-like effector nucleases. FAH-/- rabbits exhibit phenotypic features of HT1 including liver and kidney abnormalities but additionally develop frequent ocular manifestations likely caused by local accumulation of tyrosine upon NTBC administration. We also show that allogeneic transplantation of wild-type rabbit primary hepatocytes into FAH-/- rabbits enables highly efficient liver repopulation and prevents liver insufficiency and death. Because of significant advantages over rodents and their ease of breeding, maintenance, and manipulation compared with larger animals including pigs, FAH-/- rabbits are an attractive alternative for modeling the consequences of HT1.